Enhanced Viability for Ex vivo 3D Hydrogel Cultures of Patient-Derived Xenografts in a Perfused Microfluidic Platform
December 5th, 2020
5.4K views
This protocol demonstrates methods to enable extended in vitro culture of patient-derived xenografts (PDX). One step enhances overall viability of multicellular cluster cultures in 3D hydrogels, through straightforward removal of non-viable single cells. A secondary step demonstrates best practices for PDX culture in a perfused microfluidic platform.
Overview
This protocol demonstrates improved methods for the in vitro culture of patient-derived xenografts (PDX), enhancing viability and enabling high throughput screening. The approach incorporates multicellular cluster cultures in 3D hydrogels and utilizes a perfused microfluidic platform.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Cell Biology
Background
- Conventional cell lines are being replaced by patient-derived tumor samples.
- PDXs provide a more heterogeneous system reflective of native tumors.
- Improved culture methods are essential for drug screening and understanding drug mechanisms.
- Co-cultures with stroma, endothelium, and immune cells can enhance the model's relevance.
Purpose of Study
- To develop methods for extended in vitro culture of PDXs.
- To facilitate high throughput and high content screening of patient-derived tumor cells.
- To improve the assessment of drug mechanisms in a more native-like tumor environment.
Methods Used
- Removal of non-viable single cells to enhance multicellular cluster viability.
- Culture of PDXs in 3D hydrogels.
- Utilization of a perfused microfluidic platform for culture.
- Potential incorporation of additional cell types for co-culture.
Main Results
- Enhanced viability of multicellular clusters in 3D hydrogels.
- Successful implementation of a microfluidic platform for PDX culture.
- Increased potential for high throughput drug screening.
- Insights into drug mechanisms through more representative tumor models.
Conclusions
- The developed methods significantly improve the culture of patient-derived tumor samples.
- These techniques may lead to better drug screening outcomes.
- Future studies could expand on these methods by including additional cell types.
Frequently Asked Questions
What are patient-derived xenografts (PDX)?
PDXs are models created by implanting human tumor cells into immunocompromised mice, allowing for the study of human cancer in a living organism.
Why are PDX models preferred over conventional cell lines?
PDX models better reflect the heterogeneity and complexity of human tumors, providing more relevant data for drug testing.
How does the microfluidic platform enhance PDX culture?
The microfluidic platform allows for better control of the culture environment, facilitating nutrient delivery and waste removal.
What is the significance of using 3D hydrogels?
3D hydrogels provide a more natural environment for tumor cells, promoting better growth and interaction compared to traditional 2D cultures.
Can this method be used for other types of cancer?
Yes, the methods can potentially be adapted for various types of patient-derived tumors.
What future improvements are suggested for this protocol?
Incorporating additional cell types such as stroma and immune cells could enhance the model's relevance to native tumor architecture.
Executive Industry Relevance
Integrating patient-derived xenograft (PDX) clusters into 3D hydrogel cultures within perfused microfluidic platforms addresses the need for more predictive, heterogeneous tumor models in early oncology discovery. This approach enhances viability and biological fidelity, enabling high-content drug screening and mechanistic de-risking at a preclinical inflection point. The method supports translational continuity by preserving tumor architecture and heterogeneity, directly impacting portfolio triage and target validation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in biologically relevant, patient-derived systems.
- Supports functional target validation by maintaining tumor heterogeneity and microenvironmental context.
- Facilitates mechanistic de-risking through improved viability and cluster integrity.
- Provides a platform for predictive confidence in early-stage oncology programs.
Screening & Assay Development
- Prepares validated 3D PDX cultures for downstream high-throughput drug screening workflows.
- Improves assay reproducibility and standardization by depleting non-viable single cells.
- Enables quantitative viability and morphological readouts using image-based assays.
- Supports scalable, platform-based screening with microfluidic perfusion for consistent nutrient delivery.
Translational & Preclinical Research
- Aligns in vitro models with disease-relevant tumor architecture and cellular heterogeneity.
- Maintains translational continuity from discovery through preclinical validation by preserving PDX features.
- Reduces biological risk in candidate advancement by providing more predictive preclinical data.
- Facilitates biomarker exploration and mechanistic studies in a native-like tumor context.
Pipeline & Workflow Integration
This method bridges early discovery and preclinical research by enabling robust, high-fidelity PDX cultures for drug screening and mechanistic studies.
- Discovery Biology: Supports hypothesis testing and pathway clarification in patient-derived tumor systems.
- Screening: Delivers assay-ready, viable 3D cultures for reproducible compound evaluation.
- Analytics: Provides quantitative viability and morphological outputs for condition comparison.
- Translational Research: Ensures continuity with in vivo and clinical tumor characteristics.
- Enterprise Reuse: Establishes a reusable workflow for diverse PDX lines and oncology programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in oncology discovery.
- Operational Value: Standardizes culture preparation, enhances reproducibility, and supports scalability.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of oncology assets.
Implementation Considerations
- Requires expertise in 3D culture, microfluidics, and PDX handling.
- Needs access to perfused microfluidic platforms and imaging infrastructure.
- Demands cross-team standardization for cell separation and viability assessment.
- Adaptation may be necessary for different tumor types and PDX lines.
- Practical limitations include variability in tumor digestion and cluster morphology across samples.
Biopharma FAQs
Why does null hypothesis testing matter for PDX viability assays?
Null hypothesis testing in viability assays ensures that observed differences in live cell proportions between purified and non-purified PDX cultures are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit density gradient centrifugation?
Isolating viable PDX clusters via density gradient centrifugation allows teams to control for cell viability as an independent variable, clarifying the impact of purification on downstream assay performance and drug response evaluation.
What do quantitative viability measurements enable in microfluidic PDX cultures?
Quantitative viability measurements using image-based assays enable objective comparison of culture conditions, inform optimization of cluster preparation, and support data-driven decisions in screening and mechanistic studies.
Why are replication requirements critical for cross-functional PDX workflows?
Replication ensures that viability and morphological outcomes are consistent across PDX lines and experiments, facilitating reliable data sharing and collaboration between discovery, screening, and translational teams.
What statistical analysis capabilities are needed before implementing viability assays?
Teams require statistical tools to assess significance in viability and cluster distribution data, enabling confident interpretation of assay outputs and supporting go/no-go decisions in the discovery pipeline.
Chapters in this video
0:04
Introduction
1:09
PDX (Patient-Derived Xenografts) Dissociation and Initial Purification of Stromal Component
3:17
Density Gradient Centrifugation-Based Separation of PDX-Derived Clusters from Single Cells
6:03
Hydrogel Preparation and Microfluidic Plate Seeding
10:12
Results: Cell Staining and Viability Assessment
11:16
Conclusion
